What does the FDA approval of Sarclisa® (isatuximab) mean for myeloma patients?
ACP Poster: Hemorrhagic Chemosis associated with Isatuximab useПодробнее
How does the FDA approval of NGS to test for MRD in multiple myeloma affect patients?Подробнее
SARCLISA® (isatuximab) Update | Paul Richardson, MD | IMS 2022Подробнее
All About Sarclisa (Isatuximab) #myelomaПодробнее
What does the FDA approval of MRD testing for myeloma mean for patients and drug development?Подробнее
What is isatuximab? And how does it compare with daratumumab?Подробнее
Highlighting Therapeutic Options in Later Lines for Multiple MyelomaПодробнее
How important is the FDA approval of once-weekly dosage of Kyprolis for multiple myeloma patients?Подробнее
Dr. Richardson on the FDA Approval of Isatuximab in Relapsed/Refractory MyelomaПодробнее
Sarclisa (isatuximab): a newly approved drug for treatment of multiple myeloma/ plasma cell myelomaПодробнее
Understanding the FDA approved New Drug, Selinexor and its Use in Multiple MyelomaПодробнее
The recent FDA approval of IsaVRd for transplant-ineligible newly diagnosed myelomaПодробнее
Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple MyelomaПодробнее
FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapiesПодробнее
FDA Approval of Frontline Daratumumab Plus VMP in Multiple MyelomaПодробнее
The recent FDA approval of teclistamab for R/R multiple myelomaПодробнее
SARCLISA (isatuximab-irfc)- multiple myelomaПодробнее
Latest Cancer Treatments in Relapsed/Refractory Multiple Myeloma | Ask the MD | The Patient StoryПодробнее
Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple MyelomaПодробнее
Dr. Martin on FDA Approval of Denosumab in Multiple MyelomaПодробнее
